ClinicalTrials.gg
RecruitingNCT05384873MURALUpdated Nov 4, 2026

Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer

An interventional study of Immunonutrition and Control dietary intervention in Lung Cancer, Nonsmall Cell, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy — 156 open to participants now, 286 under way, 104 of them phase 3. Carcinoma, Non-Small-Cell Lung · Italy.

Planned enrollment
376th of 640
180 · median 251
Started
2023
with 45 others
No phase
25 of 716
12 open now
Primary completion
2027-07
later than 147 of 285 live
Registered
495th of 716
by date

Among the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, this one is the 376th largest by planned enrollment of the 640 interventional ones that give a count, is one of 46 that started in 2023, is one of 25 with no phase, reaches primary completion later than 147 of the 285 other live ones, and was the 495th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

156 of the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, or all of them as a file.
02

Study summary

The present study was designed to evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in non-small lung cancer patients undergoing immunotherapy and receiving nutritional counseling

03

Conditions studied

  • Lung Cancer, Nonsmall Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed histological diagnosis of non-small cell lung cancer (both squamous and non-squamous histology);
  • treatment with immunotherapy (alone or in combination with chemotherapy) for metastatic disease by investigators' choice within the framework of good clinical practice and in agreement with current guidelines;
  • Will to participate by providing written ;
  • Availability to administer oral supplements and immunotherapy with or without chemotherapy;
  • Performance Status ≤ 2;
  • ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years;
  • Inability to sign an ;
  • Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume oral nutritional supplements
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Immunonutrition

    In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs

    Dietary Supplement: Immunonutrition

  • Active comparator
    Control dietary intervention

    Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.

    Other: Control dietary intervention

Interventions

  • Dietary supplementImmunonutrition

    In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs

  • OtherControl dietary intervention

    Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    A progression-free survival rate at 12 months will be calculated, with patients categorized in a dichotomous manner as alive and progression-free or in progression or dead at 12 months.

    Time frame: 12 months

Secondary outcomes

  1. Duration of response

    Time to progression

    Time frame: 24 months

  2. Overall survival

    Overall survival

    Time frame: 24 months

  3. Treatment-related moderate-severe adverse events as assessed by Common Terminology Criteria for Adverse Events [CTCAE v5.0]

    Difference in the incidence of grade \>=3 toxicity, according to CTCAE v5.0

    Time frame: 4 months

  4. Skeletal muscle mass

    Change in skeletal muscle mass during the study evaluated with bioimpedance vectorial analysis and computed tomography scans

    Time frame: 12 months

  5. Fatigue

    Change in fatigue during the study as assessed by the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) questionnaire

    Time frame: 12 months

  6. Self-perceived quality of life

    Change in quality of life during the study as assessed by validated questionnaires

    Time frame: 12 months

  7. Self-reported physical activity level

    Change in self-reported physical activity level as assessed by the Godin's Shepard Leisure Time Exercise Questionnaire

    Time frame: 12 months

Other outcomes

  1. Serum levels of immunologic markers

    Change in levels of soluble effectors and immuno-regulatory cells during the study by cytofluorimetry and validated biochemical assays

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Caccialanza R, Cereda E, Agustoni F, Klersy C, Casirati A, Montagna E, Carnio S, Novello S, Milella M, Pilotto S, Trestini I, Buffoni L, Ferrari A, Pedrazzoli P. Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. BMC Cancer. 2022 Nov 24;22(1):1212. doi: 10.1186/s12885-022-10296-x. PubMed 36434615 ↗

Individual participant data

Plan to share: Undecided — Depending on a specific research question and according to a study protocol to be approved by the Ethics Committee

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jul 2027, 49 months after the start.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 49 months is close to that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2027 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 20, 2022
StartActual
Jun 1, 2023
Primary completionEst.
Jul 31, 2027was Jul 2026
CompletionEst.
Jul 31, 2028was Jul 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Jul 31, 2027
Nov 4, 2026
Study completion
Jul 31, 2027→Jul 31, 2028
Nov 4, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 36434615 ↗
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 36434615 ↗
    Primary completion Jul 31, 2026→Jul 31, 2027
    Study completion Jul 31, 2027→Jul 31, 2028
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05384873
Collaborators
San Luigi Gonzaga Hospital, Azienda Ospedaliera Universitaria Integrata Verona, Humanitas Hospital, Italy
Responsible party
Riccardo Caccialanza (Principal Investigator, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
May 20, 2022
Start date
Jun 1, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Riccardo Caccialanza, MD
Contact
r.caccialanza@smatteo.pv.it
0382501615 ext. 0039
Alessandra Ferrari, PharmD
Contact
alessandra.ferrari@smatteo.pv.it
0382503689 ext. 0039
Riccardo Caccialanza, MD
principal investigator · Fondazione IRCCS Policlinico San Matteo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion